Evidence map›Paper›PMID 40568465›Full record

ArticleGlobal epidemiology2025

On the current and future potential of simulations based on directed acyclic graphs.

Lutz P Breitling, Anca D Dragomir, Chongyang Duan, George Luta

Abstract read
In one paragraph

Article in Global epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lutz P BreitlingMedical Faculty, University of Heidelberg, Heidelberg, Germany.
Anca D DragomirDepartment of Oncology, Georgetown University, Washington, DC, USA.
Chongyang DuanDepartment of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
George LutaParker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiksberg, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world data are playing an increasingly important role in regulatory decision making. Adequately addressing bias is of paramount importance in this context. Structural representations of bias using directed acyclic graphs (DAGs) provide a unified approach to conceptualize bias, distinguish between different types of bias, and identify ways to address bias. DAG-based data simulation further enhances the scope of this approach. Recently, DAGs have been used to demonstrate how missing eligibility information can compromise emulated target trial analysis, a cutting edge approach to estimate treatment effects using real-world data. The importance of simulation for methodological research has received substantial recognition in the past few years, and others have argued that simulating data based on DAGs can be especially helpful for understanding various epidemiological concepts. In the present work, we present two concrete examples of how simulations based on DAGs can be used to gain insights into issues commonly encountered in real-world analytics, i.e., regression modelling to address confounding bias, and the potential extent of selection bias. Increasing accessibility and extending the simulation algorithms of existing software to include longitudinal and time-to-event data are identified as priorities for further development. With such extensions, simulations based on DAGs would be an even more powerful tool to advance our understanding of the rapidly growing toolbox of real-world analytics.

Indexed as

ConfoundingDirected acyclic graphsEmulated target trialReal world evidenceRegression modellingSelection biasSimulation studies

Identifiers

PMID40568465
PMCPMC12190896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.